NASAL VACCINES MARKET ANALYSIS

Nasal Vaccines Market, By Vaccine Type (Live attenuated vaccines, Inactivated vaccines, Subunit, recombinant, and conjugate vaccines, and Others (such as DNA vaccines, viral vector vaccines, etc.)), By Application (Influenza, COVID-19, Other respiratory infections (such as RSV, pneumococcal, etc.) and Others (such as cholera, etc.)), By Distribution Channel (Public and Private ), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Recent Developments

Partnerships & Collaborations

In October 2022, Coalition for Epidemic Preparedness Innovations partnered with Intravacc, a contract development and manufacturing organization for the development of an intranasal, broadly protective Betacoronavirus vaccine
In September 2020, Pfizer, a global biopharmaceutical company in collaboration with BioNTech SE, a biopharmaceutical company announced preliminary preclinical evidence from its BNT162b2 mRNA-based vaccine program against SARS-CoV-2, the virus that causes COVID-19 disease, in mouse and non-human primate models. Immunization with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate, protected rhesus macaques against SARS-CoV-2 infection in a non-human primate preclinical investigation via both intranasal (nose) and intratracheal (lung) routes.

Product Approvals & Launches

In January 2023, Bharat Biotech, an Indian-based global biopharmaceutical company launched iNCOVACC, a nasal vaccine used in treatment of COVID-19 in India.
In September 2022, Bharat Biotech, an India-based global biopharmaceutical company, received approval from Central Drugs Standard Control Organisation (CDSCO) for iNCOVACC (BBV154), an intranasal vaccine under Restricted Use in Emergency Situation for ages 18 and above in India for the treatment of COVID-19